Evidence map›Paper›PMID 36619649›Full record

ReviewFrontiers in medicine2022

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.

Joe M O'Sullivan, Rana R McKay, Kambiz Rahbar, Karim Fizazi, Daniel J George, Bertrand Tombal, Anja Schmall, Per Sandström, Frank Verholen, Neal Shore

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 6 countries.

Joe M O'SullivanPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast and Northern Ireland Cancer Centre, Belfast, United Kingdom.
Rana R McKayDivision of Hematology-Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.
Kambiz RahbarDepartment of Nuclear Medicine, University of Münster Medical Center, Münster, Germany.
Karim FizaziInstitut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Daniel J GeorgeDuke University School of Medicine, Durham, NC, United States.
Bertrand TombalDivision of Urology, Institut de Recherche Clinique (IREC), Cliniques Universitaires Saint Luc, Brussels, Belgium.
Anja SchmallBayer Consumer Care, Basel, Switzerland.
Per SandströmBayer HealthCare Pharmaceuticals, Whippany, NJ, United States.
Frank VerholenBayer Consumer Care, Basel, Switzerland.
Neal ShoreCarolina Urologic Research Center, Myrtle Beach, SC, United States.
Bayer (Switzerland) · CHBayer (United States) · USCarolina Urologic Research Center · USCliniques Universitaires Saint-Luc · BEDuke University · USInstitut Gustave Roussy · FRQueen's University Belfast · GBUniversity of California, San Diego · USUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radium-223 dichloride (

Indexed as

Lutetium-177-PSMAmetastatic castration-resistant prostate cancerradium-223real-world practicetargeted alpha therapy

Identifiers

PMID36619649
PMCPMC9812947
OpenAlexW4312187699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.